Bonafede, Machaon
Anaissie, Elias
Evans, Kristin
Itzler, Robbin
Article History
Received: 11 March 2021
Accepted: 6 October 2021
First Online: 20 October 2021
Declarations
:
: Not applicable – our study used only de-identified data that was obtained from an existing database (IBM® MarketScan® Research) and did not involve the collection, use, or transmittal of individually identifiable data. All database records are statistically de-identified and certified to be fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996 (HIPAA). As the database used in the study is fully de-identified and compliant with the HIPPA, this study was exempted from Institutional Review Board approval and informed consent was not needed. Permission to access the MarketScan® database was granted by Dan Barth-Jones (Columbia University).
: Not applicable – our study used only de-identified data obtained from an existing database and was compliant with the HIPPA, this study did not require patient consent for publication.
: MB is an employee of Veradigm Life Sciences and was employed at IBM Watson Health at the time the study was performed. KE is an employee of IBM Watson Health. EA is an employee of CTI Clinical Trial and Consulting Services. RI is an employee of CSL Behring.